Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABINA study of MEN1611 plus eribulin in advanced PIK3CA/PTEN-altered breast cancer
2024-512963-30-00Phase 2Authorised
- Sponsor
- MEDSIR
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of izorlisib and eribulin in triple-negative breast cancer (TNBC) and Metaplastic breast cancer (MpBC) (2 cohorts), sponsored by MEDSIR. Primary endpoint: Clinical benefit rate. Planned start May 2023; status: authorised.
02
Drugs
izorlisiberibulin
03
Conditions
triple-negative breast cancer (TNBC)Metaplastic breast cancer (MpBC)
Beyond the preview
Go deeper on 2024-512963-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512963-30-00.